The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Novel genome-wide significant germline genetic variants associated with venous thrombo-embolism (VTE) and arterial embolism (ATE) risk in patients with ALK and ROS1 fusion non-small cell lung cancer (NSCLC).
 
Sam Khan
No Relationships to Disclose
 
Beatriz Jimenez
No Relationships to Disclose
 
Katrina Hueniken
No Relationships to Disclose
 
Tianzhichao Hou
No Relationships to Disclose
 
Devalben Patel
No Relationships to Disclose
 
Tracy Stockley
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Incyte; Janssen; Merck; Pfizer
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Pfizer
Research Funding - AstraZeneca; Janssen
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche
 
Ming-Sound Tsao
No Relationships to Disclose
 
Alona Zer
Stock and Other Ownership Interests - Nixio
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; MSD; Oncohost; Oncotest/Rhenium; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche
Other Relationship - Beyond Air
 
Mor Moskovitz
No Relationships to Disclose
 
Yehuda Rosenberg
No Relationships to Disclose
 
Penelope Ann Bradbury
(OPTIONAL) Uncompensated Relationships - Abbvie; Bristol-Myers Squibb; Merck; Mirati Therapeutics
 
Lawson Eng
No Relationships to Disclose
 
Natasha B. Leighl
Honoraria - Beigene; BMS; Janssen; MSD Oncology; Takeda
Research Funding - AstraZeneca Canada (Inst); Inivata/NeoGenomics (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Adrian G. Sacher
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridgebio (Inst); CRISPR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly Loxo (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; Merck
 
Geoffrey Liu
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Jazz Pharmaceuticals; Merck; novartis; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Pfizer; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Pfizer (Inst); Roche Canada (Inst)